AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure
AstraZeneca has suffered a major setback in the PD-1 bispecific market with a Phase III non-small cell lung cancer (NSCLC) trial failure for volrustomig. This development is a blow to the company's aspirations of leading in PD-1-based bispecific antibodies for solid tumors in Western markets. Despite this, AstraZeneca is continuing volrustomig trials in various other cancers including cervical cancer, renal cell carcinoma, and mesothelioma, as well as other NSCLC patient segments.
Jennison Associates LLC Trims Stake in AbbVie Inc. $ABBV
Jennison Associates LLC significantly reduced its stake in AbbVie Inc. by 36.1% in the second quarter, selling 383,188 shares, but still holds 679,544 shares valued at $171 million. Despite this, institutional investors collectively own 70.23% of ABBV, and analysts generally maintain a "Moderate Buy" rating with an average price target of $275.95. Recent developments include AbbVie exceeding earnings expectations, a consistent quarterly dividend, and a new 52-week high, though an executive's recent $8.18 million share sale and increased leverage from an acquisition are noted as negative sentiments.
Hodges Capital Management Inc. Has $4.94 Million Stock Holdings in AbbVie Inc. $ABBV
Hodges Capital Management Inc. reduced its stake in AbbVie Inc. by 26.4% in the second quarter, now holding 19,642 shares valued at approximately $4.94 million. Despite this reduction and an $8.18 million share sale by an EVP, analyst sentiment for AbbVie remains positive with a consensus "Moderate Buy" rating and a $275.95 price target. The company reported strong Q2 earnings, exceeding expectations with $16.99 billion in revenue and $3.65 EPS, while also completing a $10 billion senior-notes offering to fund its Apogee Therapeutics acquisition.
Global Retirement Partners LLC Makes New $4.34 Million Investment in Pfizer Inc. $PFE
Global Retirement Partners LLC has made a new $4.34 million investment in Pfizer Inc., acquiring 180,182 shares during the second quarter. This comes as Pfizer reported strong quarterly earnings and revenue, exceeding analyst expectations, and maintained its fiscal 2026 EPS guidance. Despite a consensus "Hold" rating from analysts, the company declared a quarterly dividend of $0.43 per share, yielding 6.2% annually, attracting income-oriented investors amidst ongoing challenges like patent cliffs and legal settlements.
Abbott Laboratories $ABT Stock Position Raised by Financial & Tax Architects LLC
Financial & Tax Architects LLC has increased its stake in Abbott Laboratories (ABT) by 25.3%, now holding 80,248 shares valued at $7.28 million. Abbott Laboratories reported strong quarterly results, exceeding analyst expectations for EPS and revenue, and issued positive guidance for Q3 and full-year 2026. Despite ongoing litigation settlements related to infant formula, the company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $118.67.
Pfizer (PFE) Rides MRNA Cancer Optimism On A Valuation That Still Looks Modest
Pfizer (PFE) has gained renewed investor interest due to positive Phase 3 results for an mRNA melanoma treatment, boosting optimism for its oncology-focused mRNA pipeline. While the stock has seen short-term gains, longer-term recovery is still sought, with a modest 3% difference from the average analyst target. Despite a current "undervalued" narrative placing its fair value at $29.19 per share, Simply Wall St's DCF model suggests a significantly higher value of $73.31, indicating a material undervaluation.
The Options Market Gives Synopsys Room To Fall Two-Fifths Or Rise Two-Thirds
The options market indicates that Synopsys (SNPS) has a potential price band with a floor near $240 and a ceiling near $665 over the next thirteen months, representing a possible fall of two-fifths or a rise of two-thirds from its current price of $401. Despite this wide range, the implied volatility in the options market is lower than the stock's realized volatility over the past year, suggesting that the market is not bracing for heightened fear. This perceived "calm" is notable given upcoming events like Q3 earnings and the initial revenue test for the Ansys deal, whose synergies begin in fiscal 2027.
Virtus Biotech ETF (BBP) rated buy for strong biotech exposure and recent gains amid sector growth.
The Virtus Biotech ETF (BBP) is recommended as a buy due to its focused investment in FDA-approved biotech companies, strong recent performance, and an equal-weight, quarterly rebalancing strategy. Despite challenges like rising interest rates, growth in biotech sector deals and the GLP-1 market support a positive outlook. Its concentrated portfolio and cost efficiency make it attractive for long-term investors seeking biotech exposure.
Governments Ill-Fated Marijuana Decision Now Collides With the Street, the Science and the Courtroom
MMJ International Holdings, Inc. highlights three contrasting perspectives on the federal marijuana rescheduling process: advocates celebrating a potential Schedule III move, police warning of associated violence, and the courtroom's need to reconcile the government's position with its own scientific and enforcement data. The company's CEO, Duane Boise, emphasizes that a judge must consider all evidence, not just advocacy, particularly regarding the scientific reproducibility and control required for proper scheduling. MMJ also points out contradictions between the DEA's current stance and previous scientific testimony and public statements, advocating for a thorough reconciliation before a final decision.
Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead
This article examines the potential for Pfizer, Chevron, and AbbVie to reach ambitious price targets by 2027, driven by strong quarterly results and strategic initiatives. Pfizer aims for $35 with its focus on obesity and oncology, while Chevron targets $250 through its Guyana assets, Hess synergies, and a power deal with Microsoft. AbbVie eyes $325, propelled by the growth of Skyrizi and Rinvoq and its recent Apogee deal.
DataMeds AI expands Datavault AI blockchain license to all healthcare apps
DataMeds AI and Datavault AI have expanded their technology licensing agreement beyond pharmaceutical distribution to cover all healthcare, healthspan, and wellness applications. Datavault AI will now receive 19.9% of DataMeds AI's common stock, subject to closing conditions involving third-party acquisitions. This partnership aims to monetize healthcare data within a rapidly growing market, leveraging blockchain technology for patient-controlled data access and transaction models.
FDA Grants Accelerated Approval to Ultragenyx's Genglycos, First Gene Therapy for Glycogen Storage Disease Type Ia
The FDA has granted accelerated approval to Ultragenyx's Genglycos (pariglasgene brecaparvovec-opnr), a one-time AAV8 gene therapy, for patients aged eight and older with glycogen storage disease type Ia (GSDIa). This marks the first approved treatment targeting the underlying genetic cause of GSDIa, aiming to reduce cornstarch dependence. The approval was based on a study showing a significant reduction in daily cornstarch intake, though further trials are required to confirm long-term clinical benefits.
BioNTech SE - ADR (BNTX) News, Articles, Events & Latest Updates
This article provides recent news and updates concerning BioNTech SE (BNTX), highlighting its connection to the broader biotech sector. Key topics include the positive impact of Moderna-Merck's cancer vaccine success on oncology stocks like BioNTech, and Pfizer's Q2 earnings, its 2026 sales outlook, and the European Commission's authorization of a new COVID-19 vaccine formula from Pfizer and BioNTech.
BioNTech to Unveil Novel Lung Cancer Combination Data at WCLC 2026
BioNTech SE (BNTX) announced it will present new clinical data from its lung cancer development program at the IASLC 2026 World Conference on Lung Cancer, focusing on late-stage assets pumitamig and gotistobart, and mRNA-based immunotherapies. A key highlight will be the first global data for a novel combination of pumitamig and elfetabart drozuntecan in advanced lung cancer, along with updated Phase 3 overall survival data for gotistobart. While an analyst maintains a Buy rating for BNTX with a $142.00 price target, TipRanks’ AI Analyst, Spark, rates the stock as Neutral due to profitability and revenue concerns, despite a strong balance sheet and pipeline progress.
Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead
This article examines the potential for Pfizer, Chevron, and AbbVie to reach ambitious price targets by 2027, driven by strong quarterly results and strategic initiatives. Pfizer aims for $35 due to its obesity drug pipeline and cost savings, while Chevron targets $250 supported by its Guyana assets, Hess synergies, and a power deal with Microsoft. AbbVie eyes $325, propelled by the growth of Skyrizi and Rinvoq, along with an acquisition.
Can RedHill Biopharma (NASDAQ:RDHL) Show Commercial Progress Today?
RedHill Biopharma (NASDAQ:RDHL) is scheduled to report financial results today, placing scrutiny on its commercial execution, development programs, funding, and balance sheet. The article emphasizes that company-specific operational evidence regarding clinical and commercial progress, patient access, and cash discipline is more crucial than broad market assumptions. Readers should focus on qualitative signals like customer decisions, inventory movement, and alignment of capacity with demand to assess the company's real progress.
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Nurix Therapeutics has appointed Wes Burwell as its new Chief Human Resources Officer. Burwell brings over 20 years of HR leadership experience in the life sciences sector, with a strong background in scaling organizations through growth and preparing for commercialization. His appointment comes as Nurix transitions from a research-focused company to a fully integrated biopharmaceutical organization, aiming to advance its clinical pipeline and prepare for the commercial launch of its targeted protein degradation medicines.
Wealthfront Advisers LLC Sells 6,410 Shares of Amgen Inc. $AMGN
Wealthfront Advisers LLC decreased its stake in Amgen Inc. by 7.1% in the second quarter, selling 6,410 shares but still retaining 84,152 shares valued at approximately $30.5 million. Amgen reported strong Q2 earnings and revenue, exceeding consensus estimates, and declared a quarterly dividend of $2.52 per share. Despite the stock trading near its 52-week high, analyst sentiment remains mixed with an average "Hold" rating and a price target below current trading levels.
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
The U.S. FDA has accepted Teva's New Drug Application (NDA) for ecopipam and granted it Priority Review for treating pediatric patients with Tourette syndrome, targeting approval in late Q1 2027. Ecopipam is a first-in-class selective D1 receptor antagonist, representing the first novel mechanism of action in over 50 years for Tourette syndrome if approved. The NDA is supported by positive Phase 2b and Phase 3 clinical trial data, demonstrating significant reduction in tic severity and maintenance of efficacy, with a generally well-tolerated safety profile.
Main Street Financial Solutions LLC Takes $1.66 Million Position in Amgen Inc. $AMGN
Main Street Financial Solutions LLC has acquired a new stake in Amgen Inc., purchasing 4,589 shares valued at approximately $1.66 million. Amgen reported strong Q2 earnings, beating analyst estimates with $6.29 EPS and $10.05 billion in revenue, and declared a quarterly dividend of $2.52 per share. Institutional investors collectively own 76.5% of Amgen's stock, while analysts maintain a "Hold" rating with an average price target of $379.36.
Janney Montgomery Scott LLC Has $58.14 Million Stock Position in Pfizer Inc. $PFE
Janney Montgomery Scott LLC has increased its stake in Pfizer Inc. by 3.4% during the second quarter, bringing its total holdings to 2.41 million shares valued at approximately $58.14 million. Pfizer recently reported strong quarterly earnings of $0.77 per share and revenue of $15.03 billion, surpassing analyst expectations, and declared a quarterly dividend of $0.43 per share. Despite an average "Hold" rating from analysts and concerns about a looming patent cliff, the stock is showing positive sentiment due to pipeline developments and unusual call-option activity.
Eagle Health Investments LP Invests $15.92 Million in Axsome Therapeutics, Inc. $AXSM
Eagle Health Investments LP has acquired a new position in Axsome Therapeutics, purchasing 65,051 shares valued at approximately $15.92 million, making it their 15th biggest position. Other institutional investors like BlackRock Inc., Price T Rowe Associates Inc. MD, Wellington Management Group LLP, Invesco Ltd., and Geode Capital Management LLC have also significantly invested in Axsome Therapeutics, with institutional investors and hedge funds owning 81.49% of the company's stock. Despite recent insider selling and a Q2 earnings miss, analysts generally maintain a "Moderate Buy" rating with an average target price of $267.60, indicating a positive outlook for the company's future.
Amgen Inc. $AMGN Shares Sold by Danske Bank A S
Danske Bank A S reduced its holdings in Amgen Inc. by 6.8% in the second quarter, selling 29,273 shares, though other institutional investors like Norges Bank and BlackRock Inc. significantly increased their stakes. The article also details recent analyst ratings, Amgen's strong financial performance including a raised dividend, and insider share sales by SVP Nancy A. Grygiel and SVP Rachna Khosla.
Amgen Inc. $AMGN Shares Sold by Great Lakes Advisors LLC
Great Lakes Advisors LLC decreased its holdings in Amgen Inc. by 15.6% in the second quarter, selling 19,901 shares but still retaining 107,992 shares valued at $39.1 million. Despite this sale, institutional investors collectively own 76.5% of Amgen's stock. The company exceeded analyst expectations with its recent earnings report, posting $6.29 EPS and $10.05 billion in revenue, and has a consensus "Hold" rating from analysts with a target price below its current trading value.
Benjamin Edwards Inc. Purchases 28,700 Shares of Johnson & Johnson $JNJ
Benjamin Edwards Inc. has increased its stake in Johnson & Johnson (NYSE:JNJ) by 21.8%, purchasing an additional 28,700 shares. This transaction brings their total holdings to 160,633 shares valued at $40.79 million. Other institutional investors have also adjusted their positions in JNJ, while company insiders have recently sold shares.
Out of sight, out of work? What’s driving remote job cuts
Some biopharma companies are reducing their remote workforce, forcing employees to choose between returning to the office, relocating, or resigning, as seen with EMD Serono and Exelixis. While many employers cite collaboration benefits for requiring on-site presence, other factors like program cuts or cost reductions also drive layoffs, affecting both remote and on-site staff. Experts suggest that job security remains a general industry risk, regardless of work location, though some candidates are wary of changing remote work policies.
OPK Raises $125 Million Against Royalties: What Investors Should Know
OPKO Health (OPK) has secured an additional $125 million in financing by leveraging future royalties from its mazdutide license agreement with Eli Lilly and Company (LLY). This non-dilutive funding, structured as senior secured notes maturing in 2044, provides capital for OPK's extensive clinical pipeline and operating needs without issuing new equity. While it offers immediate liquidity, the company retains exposure to future royalty growth in China, but still faces execution risks associated with its pipeline and diagnostics business.
Pfizer (PFE) Reaches Deal Covering About 5,000 Federal Lawsuit Claims
Pfizer (NYSE:PFE) has established a settlement program aimed at resolving a significant portion of federal lawsuits concerning Depo-Provera intracranial meningioma, potentially covering around 5,000 of over 6,200 pending claims. This confidential agreement is a crucial legal development that could impact Pfizer's litigation reserves, risk profile, and public perception. Investors will be looking to future financial reports for clarity on the financial implications and whether the costs are within existing expectations.
Genmab Speeds Toward New Product Launches In 2027
Genmab is preparing for two new product launches in 2027, building on the commercial groundwork laid by Epkinly and Tivdak. The company's stock price has seen a significant increase following its first-half 2026 update. These upcoming launches stem from recent deals, indicating a strategic expansion of their product pipeline.
Moderna or Merck: Which Soaring Cancer Vaccine Stock Is the Better Buy?
Moderna and Merck announced a significant breakthrough with their personalized mRNA cancer vaccine, intismeran autogene, which in combination with Keytruda, met primary and secondary endpoints in a Phase 3 melanoma study. This news caused both stocks to surge, with Moderna more than doubling and Merck jumping over 10%. The article discusses the investment case for each company, highlighting Moderna's higher upside potential but also greater risk due to unprofitability, while Merck offers stronger fundamentals and incremental upside to an already robust oncology platform.
Stock Market Today, Aug. 19: Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data
Moderna's stock surged by 177% following the announcement of positive Phase 3 data for its melanoma treatment, intismeran autogene, when paired with Merck's KEYTRUDA. This significant increase in share price reflects investor optimism about the potential for intismeran in other cancer trials. The news also positively impacted other biotechnology stocks like BioNTech SE and Pfizer.
BioNTech SE Stock Pops As Traders Refocus On Oncology
BioNTech SE (BNTX) stock surged by 23.44% despite lower COVID-19 revenues and wider losses in Q2 2026, as traders are now focusing on the company's strong oncology pipeline. BioNTech boasts a substantial cash pile of €16.6 billion, active share buybacks, and 14 pivotal oncology trials, positioning it for future growth. The European Commission's approval of an updated COVID vaccine and a planned CEO transition by 2027 further support the shift towards a diversified biopharma strategy.
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?
Merck has significantly outperformed its peers, Amgen and Pfizer, in 2026, with a 44% year-to-date gain, largely due to its oncology franchise and new product launches, rather than a GLP-1 obesity drug. Amgen secured second place with a 35% gain, while Pfizer lagged with 14% but offered a compelling 6.3% dividend yield. The article notes that Merck's success came despite the sector's focus on obesity drugs this year.
Pfizer Inc Stock (PFE) Moved Up by 3.96% on Aug 19: What Signal Does It Send?
Pfizer Inc. (PFE) stock rose by 3.96% following positive clinical trial results for an mRNA cancer treatment from Merck and Moderna, which validated mRNA technology for oncology and boosted investor confidence in Pfizer's own mRNA pipeline. The increase was further supported by Pfizer's strong second-quarter financial results, which exceeded Wall Street expectations, and management's raised full-year sales guidance and expanded cost-efficiency programs. Despite long-term challenges like patent expirations and leadership instability, positive clinical news and improved fundamentals contributed to the stock's significant move.
BioNTech SE Stock Jumps As Traders Refocus On Oncology Pivot
BioNTech SE (BNTX) stock jumped nearly 20% following upbeat sentiment regarding its next-generation mRNA oncology pipeline, despite sharply lower COVID-19 revenue in Q2 2026. The company reported better-than-expected revenue and is actively shifting its focus from COVID-19 vaccines to becoming a diversified global oncology and biopharma player by 2030, supported by a substantial cash pile and numerous pivotal oncology trials. Wall Street analysts maintain bullish ratings, recognizing the strategic pivot and upcoming catalysts.
Pfizer's Obesity Push: Can Berobenatide Take Market Share?
Pfizer is making a significant strategic push into the rapidly growing obesity market, projected to reach $114 billion by 2030, primarily through its acquisition of Metsera and the development of berobenatide. While Pfizer is a late entrant compared to market leaders Eli Lilly and Novo Nordisk, its focus on convenient monthly dosing for berobenatide and other novel combinations could allow it to capture a share. Despite high execution risk and intense competition, even a mid-single-digit market share could translate into billions in revenue for Pfizer.
Insider Watch: 3 CEOs Betting Millions on Their Own Stocks
This article highlights three CEOs who have recently made significant investments in their own companies, signaling strong confidence in their respective firms. Intel's CEO purchased nearly $10 million in shares, CoStar Group's CEO bought $2.5 million worth, and Pfizer's CEO invested over $1 million. These insider buys are often seen by investors as a positive indicator for future stock performance.
Cowen & Co. keeps 'Hold' on Campbell Soup, raising price target to $22 amid sales growth and innovation.
Cowen & Co. has maintained a 'Hold' rating on Campbell Soup Company (CPB) but increased its price target from $20 to $22. This adjustment reflects Campbell Soup's successful product innovation, particularly in its Meals and Beverages division, which has led to increased sales in cooking-focused soups and the Rao's brand. The company's efforts align with growing consumer interest in home cooking and new flavors.
Protalix (PLX) Q2 2026 Earnings Call Transcript
Protalix BioTherapeutics reported strong financial results for Q2 2026, driven by Elfabrio sales and a significant milestone payment. The company reiterated its full-year 2026 revenue guidance and maintained a debt-free balance sheet with $40.7 million in cash. Protalix is advancing its PRX-115 Phase 2 RELEASE study for uncontrolled gout, with top-line results expected in late 2027, and secured a multiyear patent extension for Elfabrio in the U.S.
Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline
Sarepta Therapeutics reported strong Q2 2026 financial results, including $328.7 million in net product revenue and both GAAP and non-GAAP operating income, driven by PMO and ELEVIDYS sales. The company also announced the appointment of Michael Severino as its new CEO, who will lead Sarepta's continued advancement of its rare disease pipeline, with key data readouts for DM1 and FSHD expected in H2 2026 and a new Huntington's disease program initiated. Despite a year-over-year revenue decrease attributed to an updated ELEVIDYS label and a missed milestone payment, Sarepta narrowed its 2026 revenue guidance to $1.2 billion to $1.3 billion and ended Q2 with a robust cash position of approximately $945 million.
Regeneron Pharmaceuticals stock hits 52-week high at 821.41 USD By Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) stock reached a new 52-week high of $821.41, reflecting a 42.43% return over the past year. The company's strong performance is attributed to advancements in its drug pipeline, strategic partnerships, and robust financial health, as highlighted by InvestingPro. Recent Q2 2026 results exceeded expectations, driven by strong sales of Dupixent, Eylea HD, and Libtayo, leading to increased price targets from analysts.
Another disappointment: AstraZeneca halts Phase III lung cancer trial for volrustomig
AstraZeneca has halted a pivotal Phase III trial for its dual checkpoint inhibitor volrustomig in metastatic non-small cell lung cancer (NSCLC) because an independent committee determined the study was unlikely to meet its primary endpoints. This setback adds to recent disappointments for the company, increasing pressure to deliver new oncology products and achieve its ambitious revenue targets. Despite this, other late-stage lung cancer studies from AstraZeneca showed positive results on the same day.
Moderna and Merck personalized melanoma vaccine passes Phase 3 trial
Moderna and Merck announced that their personalized mRNA-based cancer vaccine, combined with Merck's Keytruda, met its primary and secondary endpoints in a Phase 3 trial for high-risk melanoma patients. This marks the first positive Phase 3 result for an individualized neoantigen therapy and an mRNA-based cancer treatment, showing significant improvements in recurrence-free and distant metastasis-free survival. The companies plan to present the full data and engage with regulators for potential approval filings.
Wealthfront Advisers LLC Sells 12,937 Shares of Stryker Corporation $SYK
Wealthfront Advisers LLC reduced its stake in Stryker Corporation by 25.5% in the second quarter, selling 12,937 shares and retaining 37,818 shares valued at approximately $11.9 million. Despite this, institutional investors collectively own 77.09% of Stryker, and analysts maintain a "Moderate Buy" rating with an average price target of $386.28. The company recently exceeded earnings expectations with $3.69 EPS and $6.59 billion in revenue, and declared a quarterly dividend of $0.88 per share.
M. Kulyk & Associates LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN
M. Kulyk & Associates LLC has made a new investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), purchasing 12,878 shares valued at approximately $8.03 million in the second quarter. This investment makes Regeneron Pharmaceuticals the 29th largest holding for M. Kulyk & Associates LLC, accounting for 1.3% of their total holdings. Other hedge funds have also recently increased their positions in REGN, and the company reported strong Q2 earnings, exceeding analyst expectations for both EPS and revenue.
TD Asset Management Inc Has $94.56 Million Stake in Pfizer Inc. $PFE
TD Asset Management Inc. recently reduced its stake in Pfizer Inc. by 5.5% in the second quarter, now holding 3.93 million shares valued at approximately $94.56 million. Despite institutional ownership of 68.36%, analysts generally rate Pfizer as "Hold" with a $28.28 average price target, noting a high dividend yield but also concerns about upcoming patent expirations. Pfizer exceeded Q2 earnings expectations, reporting $0.77 EPS and $15.03 billion in revenue, and projects fiscal 2026 EPS between $2.80 and $3.00.
Pallas Capital Advisors LLC Takes $1.20 Million Position in Regeneron Pharmaceuticals, Inc. $REGN
Pallas Capital Advisors LLC has acquired a new position of 1,920 shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), valued at approximately $1.20 million during the second quarter. Regeneron reported strong quarterly earnings, beating analyst estimates with an EPS of $14.29 and revenue of $4.29 billion, representing a 16.7% year-over-year increase. The company also declared a quarterly dividend of $0.94, and analysts maintain a "Moderate Buy" rating with an $801.70 target price, despite ongoing litigation risks.
Leuthold Group LLC Makes New Investment in Pfizer Inc. $PFE
Leuthold Group LLC has made a new investment in Pfizer Inc. (NYSE:PFE), purchasing over 200,000 shares valued at approximately $4.8 million during the second quarter. This comes as other institutional investors have also adjusted their stakes in the biopharmaceutical company. Analysts currently have a "Hold" rating on Pfizer, with a consensus target price of $28.28, amid ongoing concerns about patent expirations despite positive news regarding its Lyme vaccine and obesity drug pipeline.
Global Retirement Partners LLC Makes New $975,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN
Global Retirement Partners LLC has made a new investment of $975,000 in Regeneron Pharmaceuticals, Inc. by purchasing 1,564 shares during the second quarter. Other institutional investors have also adjusted their holdings, with significant stakes held by various hedge funds and institutional investors. The article also details recent insider stock sales, analyst ratings, and the company's financial performance and dividend announcement.
Is Roivant Sciences (ROIV) Fully Valued As First Quarter Results Show A Narrower Loss?
Roivant Sciences (ROIV) reported a narrower net loss in Q1 2026, though sales decreased. Despite recent share price gains and strong one-year returns, a common narrative suggests the stock is significantly overvalued, with a fair value of $10.00 compared to its current price of $37.37. This valuation concern is primarily linked to the speculative nature of its IP litigation strategy and the perceived overvaluation of its business model.
